Physician profile
Scott J Samuelson
NPI 1578677019
$2,027.65
in general payments reported to CMS, 2019-2025
26 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $194 · 2021: $108 · 2022: $92.97 · 2023: $20.94 · 2024: $550 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $338.80 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals Lp | $205.26 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $156.61 | 2020-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $130.63 | 2019-2025 | |
| Abbvie INC. | $120.84 | 2019-2025 | |
| Novo Nordisk INC | $114.95 | 2020-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.56 | 2022-2025 | Caplyta |
| Amgen INC. | $111.80 | 2019-2024 | Prolia, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $95.86 | 2019 | |
| Pfizer INC. | $88.92 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.99 | 2019-2024 | Trulance, Xifaxan |
| Cranial Technologies, INC | $45.60 | 2020-2025 | Doc Band |
| Daiichi Sankyo INC. | $42.40 | 2024 | Enhertu |
| Janssen Pharmaceuticals, INC | $40.16 | 2019-2020 | |
| Allergan, INC. | $38.96 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.26 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $36.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $31.98 | 2025 | Relexxii |
| Sanofi Pasteur INC. | $29.55 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.14 | 2025 | |
| Inspire Medical Systems, INC. | $17.74 | 2024 | Inspire |
| Corium, LLC | $17.66 | 2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $16.33 | 2024 | Rexulti |
| Abbott Laboratories | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Samuelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.